Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
04
2021
accepted:
28
06
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
16
4
2022
Statut:
epublish
Résumé
Many drugs show promising results in laboratory research but eventually fail clinical trials. We hypothesize that one main reason for this translational gap is that current cancer models are inadequate. Most models lack the tumor-stroma interactions, which are essential for proper representation of cancer complexed biology. Therefore, we recapitulated the tumor heterogenic microenvironment by creating fibrin glioblastoma bioink consisting of patient-derived glioblastoma cells, astrocytes, and microglia. In addition, perfusable blood vessels were created using a sacrificial bioink coated with brain pericytes and endothelial cells. We observed similar growth curves, drug response, and genetic signature of glioblastoma cells grown in our 3D-bioink platform and in orthotopic cancer mouse models as opposed to 2D culture on rigid plastic plates. Our 3D-bioprinted model could be the basis for potentially replacing cell cultures and animal models as a powerful platform for rapid, reproducible, and robust target discovery; personalized therapy screening; and drug development.
Identifiants
pubmed: 34407932
pii: 7/34/eabi9119
doi: 10.1126/sciadv.abi9119
pmc: PMC8373143
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).
Références
FASEB J. 2018 Jun 1;:fj201701568R
pubmed: 29856660
Mol Pharm. 2014 Jul 7;11(7):2115-25
pubmed: 24712441
Int J Pharm. 2015 Aug 1;491(1-2):170-9
pubmed: 26116013
Front Genet. 2019 May 03;10:419
pubmed: 31130992
Adv Drug Deliv Rev. 2014 Dec 15;79-80:50-67
pubmed: 25453261
Biofabrication. 2016 Oct 11;8(4):045005
pubmed: 27725343
Biomed Microdevices. 2013 Aug;15(4):583-593
pubmed: 23559404
Biomaterials. 2011 May;32(15):3862-74
pubmed: 21376390
Lab Chip. 2013 Apr 21;13(8):1489-500
pubmed: 23440068
ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9748-9761
pubmed: 33591721
Cancers (Basel). 2019 May 30;11(6):
pubmed: 31151295
Biomacromolecules. 2012 May 14;13(5):1448-57
pubmed: 22515272
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3179-84
pubmed: 26951646
Mol Cancer Res. 2008 May;6(5):675-84
pubmed: 18505913
Elife. 2017 Oct 04;6:
pubmed: 28976305
J Hematol Oncol. 2020 Jan 7;13(1):4
pubmed: 31910904
Nat Biomed Eng. 2019 Jul;3(7):509-519
pubmed: 31148598
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Sci Rep. 2016 Aug 23;6:31589
pubmed: 27549930
Adv Mater. 2019 Mar;31(10):e1806899
pubmed: 30663123
ACS Nano. 2016 Feb 23;10(2):2028-45
pubmed: 26815014
J Cereb Blood Flow Metab. 2018 Oct;38(10):1667-1681
pubmed: 30058456
J Health Econ. 2016 May;47:20-33
pubmed: 26928437
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Sci Adv. 2019 Sep 06;5(9):eaaw2459
pubmed: 31523707
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
J Neurooncol. 2005 Sep;74(3):249-60
pubmed: 16187022
Cancer Res. 2016 Aug 1;76(15):4359-71
pubmed: 27261506
Cancer Res. 2009 Feb 1;69(3):836-44
pubmed: 19176381
Front Cell Neurosci. 2018 Aug 03;12:235
pubmed: 30123112
Nat Commun. 2021 Mar 26;12(1):1912
pubmed: 33771989
Oncogene. 2017 Aug 31;36(35):5006-5022
pubmed: 28459461
Biomaterials. 2012 Jun;33(17):4353-61
pubmed: 22429982
Biofabrication. 2014 Sep;6(3):035001
pubmed: 24722236
Cancer Res. 2002 Nov 1;62(21):6270-7
pubmed: 12414657
Biochem Biophys Res Commun. 2018 Feb 26;497(1):32-38
pubmed: 29408502
Semin Cancer Biol. 2010 Jun;20(3):128-38
pubmed: 20599506
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Materials (Basel). 2019 Sep 11;12(18):
pubmed: 31514390
Nat Biotechnol. 2014 Aug;32(8):760-72
pubmed: 25093883
Expert Opin Drug Deliv. 2020 Jan;17(1):9-21
pubmed: 31971041
Biomed Microdevices. 2014 Feb;16(1):127-32
pubmed: 24150602
Sci Adv. 2020 Mar 06;6(10):eaay7513
pubmed: 32181351
Cancer Res. 2019 Feb 1;79(3):423-436
pubmed: 30679177
Nat Rev Cancer. 2009 Feb;9(2):108-22
pubmed: 19165226
Acta Biomater. 2014 Oct;10(10):4236-46
pubmed: 25034645
J Comp Neurol. 2016 Dec 15;524(18):3865-3895
pubmed: 27187682
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
ACS Biomater Sci Eng. 2016 Oct 10;2(10):1710-1721
pubmed: 28251176
Cancer Res. 2007 Mar 15;67(6):2666-75
pubmed: 17363587
Int J Mol Sci. 2019 Apr 30;20(9):
pubmed: 31052281
PLoS One. 2009;4(4):e5233
pubmed: 19381291
Nature. 2018 Aug;560(7718):325-330
pubmed: 30089904
Small. 2021 Apr;17(15):e2006050
pubmed: 33502104
Int J Mol Sci. 2019 Oct 12;20(20):
pubmed: 31614713
Cancer Res. 2000 May 1;60(9):2497-503
pubmed: 10811131
Nat Commun. 2019 Jun 11;10(1):2541
pubmed: 31186414
Cell Res. 2020 Oct;30(10):833-853
pubmed: 32499560
Adv Mater. 2019 Apr;31(14):e1806590
pubmed: 30702785
Oncotarget. 2015 Oct 13;6(31):31479-92
pubmed: 26362401
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
PLoS One. 2012;7(9):e44395
pubmed: 22970208